circulating tumor DNA
With $8 million in seed funding, Droplet is developing a test for minimal residual disease detection in head and neck cancer, with research ongoing for other promising targets.
Neogap Therapeutics, Simsen Diagnostics Collaborate on Cancer Dx
The companies will examine circulating tumor DNA in blood samples from patients participating in Neogap's Phase I/II clinical trial.
Data from an early-phase trial has spurred the firm to validate its blood-based residual disease assay, Radar, in neoadjuvant bladder cancer.
The Canadian company plans to test the clinical utility of its targeted 90-marker panel in monitoring patient response to therapy.
New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions
The data, from a large prospective cohort, support the value of chemotherapy for ctDNA-positive patients, regardless of clinical stage.